A
ACEA Biosciences
Evelopment and commercialization of high performance cell analysis platforms for life science research
About ACEA Biosciences
ACEA Biosciences Inc., founded in 2002 by Lin Jixun and Feng Lin, operates as a developer of cell analysis instruments for the life science research market. The company established its headquarters in San Diego, California, with significant manufacturing and R&D operations located in Hangzhou, China. A major milestone in the company's history was the acquisition by Agilent Technologies in September 2018 for $250 million in cash, a strategic move for Agilent to expand its footprint in the cell analysis sector.
The company's business model revolves around the development, manufacturing, and sale of advanced cell analysis platforms to academia, as well as the biotech and pharmaceutical industries. These instruments are utilized in a wide range of applications, including preclinical drug discovery and development, toxicology, and safety pharmacology. ACEA Biosciences generates revenue through the sale of its instrument systems, associated software, and consumables. Before its acquisition, the company had successfully raised $37.9 million in funding over two rounds to support its growth and product development.
ACEA is recognized for two main product lines: the xCELLigence Real-Time Cell Analysis (RTCA) systems and the NovoCyte benchtop flow cytometers. The xCELLigence platform utilizes non-invasive microelectrodes in multiwell plates to monitor cellular behavior like growth, function, and responses to treatments in real-time, without the need for labels. This provides researchers with information-rich data from various cell-based assays. The NovoCyte portfolio offers high-performance, customizable flow cytometers that enable multi-parameter cellular analysis, capable of detecting up to fifteen parameters. These systems are designed to be intuitive, with automated maintenance functions and flexible configurations to meet diverse research needs.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2002
- Headquarters
- San Diego, United States
- Employees
- 54
- Open positions
- None listed
- Dealroom signal
- 64.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Analytics, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Mar 2019 | $20M | $80M | Qiming Venture Partners | — |
| ACQUISITIONOther financing | Sep 2018 | $250M | $250M | Agilent | — |
Growth signals
Latest recorded traffic for ACEA Biosciences is 380 monthly website visits, up 245.5% over the last three months. ACEA Biosciences's team declined 29.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
ACEA Biosciences in the San Diego ecosystem
The ACEA Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Lilly Asia Ventures
Series B and later1 investor entered at this stage
Other known investors1 additional known investor
Agilent
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ACEA Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ACEA Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









